Evolving Treatment Algorithms for the Management of Nonmetastatic, Castrate-Resistant Prostate Cancer

View Activity

PROGRAM CHAIR

Neal Shore, MD
Director CPI
Carolina Urologic Research Center
Myrtle Beach, SC

FACULTY

Thomas Cartwright, MD
Co-Chairman, US Oncology GI Research
Associate Professor of Medicine
University of Central Florida College of Medicine
Ocala, FL

PROGRAM OVERVIEW

This enduring activity will cover the treatment and management of patients with prostate cancer.

TARGET AUDIENCE

This CME initiative is designed to meet the educational needs of urologists, medical oncologists, oncology nurses, and other health care providers involved in the treatment of patients with prostate cancer.

LEARNING OBJECTIVES

Upon completion of the program, attendees should be able to:

  • Describe the clinical characteristics associated with nonmetastatic CRPC and the factors that predict poor survival and rapid development of metastases
  • Evaluate emerging treatment options for patients with nonmetastatic CRPC on the basis of clinical safety and efficacy data
  • Identify how treatment selection for patients with nonmetastatic prostate cancer may inform treatment selection in the metastatic setting and the development of patient-personalized treatment plans across the course of disease

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent for their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment and management of patients with prostate cancer.

CNE Credits:
1.0 ANCC Contact Hour

CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME)
Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

PROGRAM CHAIR
Neal Shore, MD reports that he has served as a consultant for Abbvie, Bayer, Dendron, Merck & Co, Pfizer, Janssen, and Sanofi-Aventis.

FACULTY
Dr. Cartwright reports that he has served on speakers bureaus for Amgen and Taiho.

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Chris Drury, Medical and Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
Sharine Griggs, Program Manager for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the online activity.
3. Submit the evaluation form to Med Learning Group.

You will receive your certificate after completion of the activity.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: March 15, 2019

EXPIRATION DATE: March 15, 2020

View Activity

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.